We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Prestige BioPharma (“Prestige”) announced today that it has reached a licensing agreement with Cipla Limited (“Cipla”) for its trastuzumab biosimilar (HD201) under which......